Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 243

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 243
---
,071,651, with a pending U.S. continuation, and issued patent in Canada and pending foreign applications in China, Europe, and Hong Kong), our custom-made Synthetic DNA controls (covered by U.S. Patent Nos. 11,646,100 and 12,176,066, with a pending U.S. continuation, an issued patent in Canada, and pending applications in China, Europe, and Hong Kong), and our proprietary signal processing technology (covered by U.S. Patent Nos. 11,430,543 and 12,183,437, also granted in Brazil, Japan, Singapore, South Korea, Israel, Canada, Australia and Europe, and pending in China, Hong Kong, and India), all of which is used to maximize readings taken from single blood draws. We have also recently filed several unpublished patent applications covering a range of techniques for improving the efficiency and accuracy of DNA sequencing-based assays. In addition, we file for patent protection in connection with our ongoing research and development activities, particularly those related to early-stage cancer detection. Our patents and applications generally fall into three broad categories:

| - |     | detecting and monitoring cancer and other diseases by determining genetic variations and other biomarkers in biological samples; |

| - |     | methods for preparing and sequencing cfDNA, techniques for enriching nucleic acid samples, identifying cfDNA, and detecting epigenomic variations (such as DNA methylation) in biological samples; and |

| - |     | precision diagnostics, including biochemical and analytical techniques for obtaining and analyzing genetic information to detect genetic abnormalities in relatively small complex samples, such as fetal cfDNA using 
 reflex single-gene noninvasive prenatal screening.                                                                                                                                                                    |

175

The following table includes our U.S. patents granted and U.S. patent applications published as of June 30, 2025, along with the status in other jurisdictions (excluding divisional and continuation patents and applications). All patents are utility patents. We have additional patent applications that have not yet published as of June 30, 2025. BillionToOne Patent Portfolio

| Patent 
 Family |     | Patent Name                                                                         |     | Summary                                                                                                                                                                                                                                             |     | U.S. Patent 
      Number |     | U.S. Exp. 
 Date      |     | Other Jurisdictions |
| P01    |     | Dilution Tagging for Quantification of Biological Targets                           |     | Method for accurate determination of biological target abundance that can include generating a first set of molecules associated with a target sequence that includes dil